NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Prolong Pharmaceuticals, LLC

Prolong Pharmaceuticals, LLC

Private
South Plainfield, New JerseyHealthcare & Life Scienceshttps://www.prolongpharma.com/

Last Round

Grant

Nov 3, 2010

Total Funding Raised

$30.24M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Prolong Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company developing therapies for ischemia and hypoxia in disorders like stroke, sickle cell disease, and cystic fibrosis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

ischemia therapyhypoxia therapyclinical-stage biotechacute ischemic strokePEGylation technologyoxygen carrierstroke treatmentcarbon monoxide-releasing moleculeblood substitutedrug delivery platformbreakthrough therapysickle cell diseaseAISprotein therapeuticscGMP manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Prolong Pharmaceuticals, LLC Comparables

Compare Prolong Pharmaceuticals, LLC with similar companies based on industry and business-model similarity.

Prolong Pharmaceuticals, LLC comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NuvOx Therapeutics
86%
HbO2 Therapeutics
83%
Pharmazz, Inc.
81%

Prolong Pharmaceuticals, LLC Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 3, 2010
Series COct 14, 2010
Early FundingApr 15, 2005

Prolong Pharmaceuticals, LLC Investors

Notable investors and investment history

Prolong Pharmaceuticals, LLC investors
InvestorRounds
Avtar InvestmentsSeries C
KBL Healthcare VenturesSeries C
Internal Revenue ServiceGrant
Tarsadia InvestmentsSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 21, 2026

    Monthly visitors grew 60% MoM, from 485 to 776.

  • Nov 10, 2025

    Monthly visitors increased 40% MoM.

Prolong Pharmaceuticals, LLC Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Prolong Pharmaceuticals, LLC Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Prolong Pharmaceuticals, LLC's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth Plainfield, New Jersey
Employee Range18
Year Founded2005
Last FundingNov 3, 2010

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.